NIH R01 · 2025
The goal of this proposal is to better understand a novel signaling axis initiated in prostate cancer (PCa) patients by next-generation androgen receptor signaling inhibitors (ARSIs). The standard use of ARSIs in PCa patients help limit tumor progression, but inevitably result in the development of therapeutically resistant disease. We have identified a synthetic lethal relationship established when ARSI is combined with CD105 antagonist, carotuximab, based on the finding that ARSI promote CD105 up regulation by PCa epithelia and associated stromal fibroblasts, and bone morphogenic protein (BMP) signaling downstream of CD105 receptor signaling support multiple mechanisms of ARSI resistance.…
From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.